6.96
0.01 (0.14%)
Penutupan Terdahulu | 6.95 |
Buka | 6.85 |
Jumlah Dagangan | 133,799 |
Purata Dagangan (3B) | 1,336,895 |
Modal Pasaran | 1,082,718,592 |
Harga / Jualan (P/S) | 11.65 |
Harga / Buku (P/B) | 7.55 |
Julat 52 Minggu | |
Tarikh Pendapatan | 7 Aug 2025 |
Margin Keuntungan | -107.04% |
Margin Operasi (TTM) | -542.82% |
EPS Cair (TTM) | -0.750 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -26.80% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 13.13% |
Nisbah Semasa (MRQ) | 2.95 |
Aliran Tunai Operasi (OCF TTM) | -180.63 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -133.93 M |
Pulangan Atas Aset (ROA TTM) | -30.02% |
Pulangan Atas Ekuiti (ROE TTM) | -105.50% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Wave Life Sciences Ltd. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | 1.00 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Mid Growth |
% Dimiliki oleh Orang Dalam | 16.25% |
% Dimiliki oleh Institusi | 84.41% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
M28 Capital Management Lp | 31 Mar 2025 | 5,664,548 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 18.00 (Wedbush, 158.62%) | Beli |
Median | 15.00 (115.52%) | |
Rendah | 10.00 (Cantor Fitzgerald, 43.68%) | Beli |
Purata | 14.50 (108.33%) | |
Jumlah | 4 Beli | |
Harga Purata @ Panggilan | 7.33 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Citigroup | 16 Jul 2025 | 16.00 (129.89%) | Beli | 7.82 |
Wedbush | 23 Jun 2025 | 18.00 (158.62%) | Beli | 6.96 |
Raymond James | 11 Jun 2025 | 14.00 (101.15%) | Beli | 7.19 |
Cantor Fitzgerald | 29 Apr 2025 | 10.00 (43.68%) | Beli | 7.34 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
20 Jun 2025 | Pengumuman | Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions |
29 May 2025 | Pengumuman | Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference |
28 May 2025 | Pengumuman | Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer |
08 May 2025 | Pengumuman | Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update |
01 May 2025 | Pengumuman | Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |